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Abstract
Background: Resistance to preoperative radiotherapy is a major clinical problem in the treatment for locally
advanced rectal cancer. The role of NDRG1 in resistance to ionizing radiation in rectal cancer has not been fully
elucidated. This study aimed to investigate the effect of the reduced intracellular NDRG1 expression on radio-
sensitivity of human rectal cancer cells for exploring novel approaches for treatment of rectal cancer.
Methods: Three radio-resistant human rectal cancer cell lines (SNU-61R80Gy, SNU-283R80Gy, and SNU-503R80Gy)
were established from human rectal cancer cell lines (SNU-61, SNU-283, and SNU-503) using total 80 Gy of
fractionated irradiation. Microarray analysis was performed to identify differently expressed genes in newly
established radio-resistant human rectal cancer cells compared to parental rectal cancer cells.
Results: A microarray analysis indicated the RNA expression of five genes (NDRG1, ERRFI1, H19, MPZL3, and UCA1)
was highly increased in radio-resistant rectal cancer cell lines. Short hairpin RNA-mediated silencing of NDRG1
sensitized rectal cancer cell lines to clinically relevant doses of radiation by causing more DNA double strand
breakages to rectal cancer cells when exposed to radiation.
Conclusions: Targeting NDRG1 represents a promising strategy to increase response to radiotherapy in human
rectal cancer.
Keywords: Rectal cancer, Paired rectal cancer cell lines, Establishment, Radiation, Resistance, Gene expression,
NDRG1, ERRFI1, Microarray
Background
Colorectal cancer (CRC) is the second most common
cause of cancer related deaths in developed countries
[1]. Adjuvant chemo- and radio-therapy (RT) with total
mesorectal excision (TME) has been a standard ap-
proach for rectal cancer patients [2]. Preoperative RT
significantly attenuated recurrence rate of rectal cancer
especially with a negative circumferential margin [3]. In
spite of initial clinical responses, a large portion of
patients experience resistance to RT, which is the major
cause of rectal cancer-related mortality [4]. Therefore,
identifying functionally relevant biomarker to
radio-resistant rectal cancer would promote the clinical
efficacy of RT.
A wide variety of molecular alterations including
chromosomal aberrations and genetic polymorphisms
lead to radio-resistance [5]. Although a number of
potential targets such as Survivin [6] and TCF4 [7] have
been identified, the heterogeneity of radio-resistant rec-
tal cancer emphasizes necessity of various in vitro
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models representing diverse genetic backgrounds and
radio-sensitivity [8]. Thus, we newly established three
radio-resistant human rectal cell lines, and analyze their
changes in mRNA expression using microarray. Five
genes (NDRG1, ERRFI1, H19, MPZL3, and UCA1) were
selected as potential candidates. Among them, ERRFI1
and NDRG1 became final gene of interest as their
mRNA and protein expression level was highly increased
in radio-resistant rectal cancer cells.
The protein expression of ERRFI1 (ERBB receptor
feedback inhibitor, also known as MIG6 or GENE33),
which is a negative regulator of EGFR, is reported to be
down-regulated in skin, breast, pancreatic, ovarian, and
liver cancer [9, 10], and augmented protein expression
of EGFR is known to be involved with radio-resistance
[11]. Although ERRFI1 has been studied with regard to
drug-resistance in colorectal cancer [12], its role in
radio-resistance has not been studied yet. N-myc
downstream-regulated gene 1 (NDRG1) has been re-
ported as a possible metastasis suppressor by maintain-
ing the localized E-cadherin and β-catenin in prostate
and colon cancer cells [13]. In addition, the neuroblast-
oma study revealed that overexpression of NDRG1
causes increased level of resistant-related proteins such
as MDR, LRP-1, and MRP-1 [14]. Nevertheless, its role
in resistance to ionizing radiation in rectal cancer cell
lines has not been revealed.
Methods
Establishing radio-resistant rectal cancer cell lines and cell
culture condition
Seven rectal cancer cell lines (SNU-61, SNU-283,
SNU-503, SNU-977, SNU-977R80Gy, SNU-1411, and
SNU-1411R80Gy) were provided by the Korean Cell
Line Bank (Seoul, Korea). Catalogues numbers of the cell
lines were 00061, 00283, 00503, 00977, 00977-RAD,
01411, and 01411-RAD respectively. A total of 80 Gy of
fractionated ionizing radiation were irradiated to three
rectal cancer cell lines (SNU-61, SNU-283, and
SNU-503) over 40 times by using Cesium-137 irradiator.
The established radio-resistant rectal cancer cell lines
were deposited by Korean Cell Line Bank. The cata-
logues numbers of the established radio-resistant rectal
cell lines are 00061/R80GY, 00283/R80GY, and 00503/
R80GY. All cell lines were cultured in RPMI1640 media
with 10% FBS and penicillin (100 units/ml)-streptomycin
(100μg/ml) (Thermo Fisher Scientific, CA, USA).
DNA fingerprinting analysis
A DNA fingerprinting analysis is used to authenticate
each cell line. The genomic DNA from each cell line was
amplified using the AmpFlSTR identifiler PCR amplifica-
tion kit (Applied Biosystems, Foster City, CA, USA). A
single PCR amplified 15 tetranucleotide repeat loci
(CSF1PO, D2S1338, D3S1358, D5S818, D7S820, D8S1179,
D13S317, D16S539, D18S51, D19S433, D21S11, FGA,
TH01, TPOX, and vWA) and Amelogen gender determin-
ing marker at loci containing highly polymorphic micro-
satellite markers. Amplified products were analyzed using
an ABI 3730 genetic analyzer (Applied Biosystems). The
STR profiles of established radio-resistance rectal cancer
cell lines and their parental cell lines are listed in
Additional file 1: Table S2.
Cell counting
3.0 × 105 cells were seeded in 3 ml of culture medium
onto 6-well plates. Cells were maintained in humidified
incubators at 37 °C in an atmosphere of 5% CO2 and
95% air for 24 h. Cells were exposed to 4 Gy of radiation
using Cs-137 irradiator and stained with 0.4% trypan
blue. The number of viable cell were counted using the
Countess™ cell counting chamber slide (Invitrogen,
Carlsbad, CA, USA) and Countess™ automated cell
counter (Invitrogen) for 96 h in 24 h intervals. Every
process was repeated three times for each cell line.
Cell viability assay
0.5 × 105 cells were seeded on 96 well plates with 0.5 ml
of RPMI1640 media with 10% FBS and 1.1% penicillin
for the cell viability assay. Meanwhile, 7.5 × 105 cells
were simultaneously seeded on a T75 flask with 15 ml of
RPMI1640 media at 10% FBS and 1.1% penicillin for
Western Blotting. After 24 h of incubation at 37 °C in a
5% CO2 and 95% air atmosphere, cells were exposed to
12 Gy of Cs-137. In a time course manner (6, 24, 48,
and 72 h after irradiation), 10 μl of EZ-Cytox solution
(Daeil Lab, Seoul, Korea) was added to each well of 96
well plates. After 2 h of incubation at 37 °C, the optical
density was measured at 450 nm by Multiskan™ GO Mi-
croplate Spectrophotometer (Thermo Fisher Scientific,
Waltham, MA, USA). 1.0 × 105 cells were seeded on 96
well plates with 0.5 ml of RPMI1640 media at 10% FBS
and 1.1% penicillin, which were irradiated with 0 and
4 Gy of Cs-137 after 24 h. 50 μl of MTT [3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium brom-
ide] (Sigma-Aldrich co., St, Louis, MO, USA) solution
diluted with PBS (2.5 mg/ml) was added to each well of
the 96-well plates at the same time interval as the cell
counting (0 and 96 h). After 4 h of incubation, the MTT
solution was removed and 150 μl of DMSO (dimethyl
sulfoxide) was added. The absorbance was measured by
an ELISA reader (Molecular Devices Co., CA, USA) at
540 nm after being incubated for 15 min at room
temperature.
Cell cycle analysis by FACS
7.5 × 105 cells were seeded on a T75 flask with 15 ml of
RPMI1640 media with 10% FBS and 1.1% penicillin.
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After 24 h of incubation at 37 °C in an atmosphere of
5% CO2 and 95% air, cells were exposed to 4 Gy of
Cs-137 and collected 96 h after irradiation. Collected
cells were fixed with 70% ethanol and incubated at 4 °C
for 24 h. After washing with cold DPBS, cells were
stained with propidium iodide (PI) (100 μg/ml)
(Sigma-Aldrich Co.) and RNase A (10 mg/ml) (Intron bio-
technology, Gyeonggi, Korea) for 30 min on ice. Then, a
fluorescence-activated cell sorter (FACS CantoII™, BD, NJ,
USA) was used to analysis the cell cycle phases.
Colony forming assay
1.5 ml of 0.5% noble agar (BD Difco™, Franklin Lakes,
NJ, USA) in RPMI1640 with 10% FBS was solidified at
the bottom of each individual well in a 6-well plate. 3.5 ×
103 cells in 500 μl of RPMI1640 media with 10% FBS
and 1.1% penicillin were mixed with 500 μl of 0.4% agar
and spread on the bottom agar. After 24 h of incubation
at 37 °C in an atmosphere of 5% CO2 and 95% air, the
plate was irradiated with 4 Gy of Cs-137. Every 5 d
300 μl of RPMI1640 media at 10% FBS and 1.1% penicil-
lin was added to prevent desiccation of agar media.
Three weeks later, the colonies were stained with 500 μl
of 0.05% crystal violet and counted under a
phase-contrast microscope. The number of colonies
from triplicated wells was averaged.
Microarray analysis
Total RNA was extracted from induced radio-resistant
and parental cell lines using TRIzol (Invitrogen, Carlsbad,
CA, USA) and purified with the RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to manufacturer’s instruc-
tions. The RNA integrity was assessed by an Agilent 2100
Bioanalyzer (Agilent, Palo Alto, CA, USA). High quality
RNA (RNA integrity number > 9.0) was used for the gene
expression microarray analysis in which 100 ng of total
RNA was processed for biotin labeled target preparation
and hybridization to the Affymetrix Gene 1.0 ST array ac-
cording to manufacturer’s instructions in order to perform
the gene expression profiling experiments (Affymetrix,
Inc., Santa Clara, CA, USA). After 16 h of hybridization at
45 °C and rotating at 60 rpm, the arrays were washed and
stained on a GeneChip Fluidics Station (Affymetrix, Inc.)
and scanned using the Gene Chip Scanner 3000 (Affyme-
trix, Inc.). The CEL intensity data extracted by GCOS
(Gene Chip Operating Software) was used for the data
analysis and raw data were processed using the Affyme-
trix® Expression Console software with the default RMA
parameters.
RNA isolation and cDNA synthesis
Cells were collected by trypsinization and suspended in
TRIzol (Invitrogen, Carlsbad, CA, USA). The total RNA
was isolated with the RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to manufacturer’s instructions. For
cDNA synthesis, QuantiTect Reverse Transcription Kit
(Qiagen) is used. 1 μg of total RNA, 2 μl of gDNA Wipe-
out Buffer, and DEPC water filled up to 14 μl were
mixed together and incubated at 42 °C for 2 min. The
mixture was then blended with Quantiscript RT Buffer,
RT Primer Mix, and Quantiscript® Reverse Transcriptase,
and incubated at 42 °C for 45 min. The mixture was fur-
ther incubated at 95 °C for 2 min and cooled down to
room temperature.
Reverse transcriptase-PCR (RT-PCR)
Synthesized cDNA was diluted to 100 ng/μl using dis-
tilled water. 1 μl of 100 ng/μl cDNA was amplified in
14 μl of a PCR mixture that contained 1.5 μl of 10 x
PCR buffer (with MgCl2), 0.5 μl of dNTP, 0.25 μl of for-
ward primer (10 pmol/ul), 0.25 μl reverse primer
(10 pmol/ul), 11.42 μl of distilled water, and 0.08 μl of
i-Taq DNA polymerase (500 units) (Intron biotechnology,
Gyeonggi, Korea). The primer sequences that were used
in this study are listed in Additional file 1: Table S1.
RT-PCR was performed using a programmable thermal
cycler (PCR System 9700, Applied Biosystems; Foster City,
CA, USA) and the RT-PCR products were fractionated on
a 1.5% agarose gel containing ethidium bromide (EtBr).
Real-time PCR
Synthesized cDNA was diluted to 10 ng/μl and each pri-
mer concentration was optimized. 1 μl of cDNA was
mixed with 5.0 μl of Master Mix (Applied Biosystems),
distilled water, and optimized volume of each forward
and reverse primer. The primer sequences were the
same as the ones used in RT-PCR, as listed in Additional
file 1: Table S1. A real-time PCR analysis was performed
with the 7900HT Fast Real-Time PCR System (Life
Technologies Co., Carlsbad, CA, USA) and the results
were normalized to the housekeeping gene, β-actin, and
the cycle threshold (Ct) values were extracted.
Protein isolation and western blotting
0.5 × 105 cells were seeded on 96 well plates with 0.5 ml
of RPMI1640 media with 10% FBS and 1.1% penicillin
for the cell viability assay while 7.5 × 105 cells were sim-
ultaneously seeded on a T75 flask with 15 ml of
RPMI1640 media with 10% FBS and 1.1% penicillin for
Western Blotting. Cells were harvested with a cell
scraper after washing with cold PBS. Whole protein was
extracted with EzRIPA buffer (ATTO Co., Tokyo,
JAPAN) supplied with 1% protease inhibitor and 1%
phosphatase inhibitor in accordance with the cell viabil-
ity assay time frame. The volume of lysis buffer was
adjusted to the number of cells collected in each vial.
The protein concentration was determined by SMART™
micro BCA protein assay kit (Intron biotechnology,
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Gyeonggi, Korea). Equal amounts of protein were loaded
on 4–15% Mini-PROTEAN TGX™ Precast Gels (BIO-RAD,
Hercules, CA, USA) and blotted at 50 voles for 2 h. Pro-
teins were then transferred to Trans-Blot Turbo™ Transfer
Pack (BIO-RAD) using Trans-Blot Turbo™ Transfer System
V1.02 machine (BIO-RAD) at 2.5 Amp and 25 Volt. The
membrane was incubated in 2.5% skim milk containing
0.5% Tween 20 for an hour at room temperature. Primary
antibodies against NDRG1 (abcam, Cambridge, United
Kingdom) (1:5000), ERRFI1 (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA) (1:1000), PARP (BD Biosci-
ences, San Jose, CA, USA) (1:1000), Caspase-3 (abcam,
Cambridge, United Kingdom) (1:2000), and β-actin (Ap-
plied Biological Materials Inc., Richmond, BC, Canada)
(1:5000) were diluted with 1.5% skim milk (BD Biosciences,
CA, USA) containing 0.5% Tween 20 and introduced to
the membrane. After 2 h at room temperature, Peroxidase
conjugated mouse or rabbit IgG antibody (Jackson Immu-
noresearch, West Grove, PA, USA) (1:5000) was added as a
secondary antibody. A chemiluminescent working solution,
WESTZOL™ (Intron biotechnology), was decanted
into the membrane, which was then exposed to Fuji
RX film (Fujifilm, Tokyo, Japan) for 1–5 min.
Immunofluorescent staining
Cells were seeded on chambered coverglass (Thermo
Fisher Scientific, MA, USA) at densities of 3 × 103 to 2 ×
104 cells/mL in culture media, according to diverse cell
growth rates and desirable cell confluency. After 72 h,
cells were washed with DPBS three times before being
fixed and permeabilized using BD Perm/Wash™ (BD
bioscience, CA, USA). After cells were washed with
washing solution (BD bioscience, CA, USA), a PBS solu-
tion containing 2% FBS (GE Healthcare Life Sciences,
Buckinghamshire, UK) was added. Primary antibodies
that were used for Western Blotting were applied for im-
munofluorescent staining at dilution factors of NDRG1
(1:50), ERRFI1 (1:100), PARP (1:100), and Caspase-3
(1:100). 1 to 2 h after the primary antibody was applied,
cells were washed with cold PBS containing 0.05% of
tween 20. A conjugated secondary antibody (Thermo
Fisher Scientific, MA, USA) was applied for 1 to 2 h in
accordance with matched species. After cells were
washed with cold PBS containing 0.05% of tween 20, dis-
tilled water with 1× DAPI and Rhodamine-conjugated
Phalloidin (Sigma-Aldrich, MO, USA) was added for
20 min. Finally, the cells were washed with DPBS three
times and viewed using a LSM800 Confocal Laser
Scanning Microscope (Carl Zeiss, Oberkochen, Germany).
Knockdown of ERRFI1 expression by siRNA transfection
2.0 × 105 cells of SNU-503R80Gy with 1 ml of culture
media were seeded in a 6-well plate and transfected with
control siRNA and ERRFI1 siRNA (No#:1048480) (Bioneer,
Alameda, CA, USA) with lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) at a final concentration of 40 nM
siCONT and 40 nM siERRFI1 in Opti-MEM medium for
6 h. The media was then replaced with an equal volume of
RPMI1640 (Gibco) without antibiotics. Consequently, the
cells were collected for cell counting and cell viability assay
for confirmation of the mRNA level.
Knockdown of NDRG1 expression by shRNA transduction
4 × 104 of 293FT cells with 10 ml of DMEM media sup-
plied with 10% of FBS and 1% of penicillin streptomycin
were seeded on 100 pi tissue culture. After 24 h of incu-
bation, the culture media was changed to 10 ml of
Opti-MEM, and ViraSafe™ Lentiviral Packaging System,
Pantropic (CELL BIOLABS, INC., San Diego, CA, USA)
with short hairpin RNA targeting NDRG1 (Sigma-Aldrich
co., St, Louis, MO, USA) was treated with Lipofectamine
3000 (Invitrogen) in accordance with manufacturer’s
protocol. After 48 h, the viral soup was harvested and
filtered through a 0.45 μm pored filter (Sartorius Stedim
Biotech SA, Göttingen, Germany). The resulting harvested
viral soup was aliquoted into a 1.5 mL tube and kept at −
70 °C. 1 × 105 cells/ml of SNU-503R80Gy cells were
seeded on 24 well tissue culture plates in 0.5 ml of
RPMI1460 medium and incubated at 37 °C overnight.
Viral transduction was performed using ViraDuctim™
(CELL BIOLABS, INC., San Diego, CA, USA) according
to manufacturer’s protocol. The efficacy of shRNA on
down-regulating NDRG1 was confirmed by Western Blot.
Statistical analysis
All acquired data in this study were analyzed by GraphPad
Prism 5.0 and expressed as mean ± standard deviation. A
comparison between the two cell lines (SNU-503 and
SNU-503R80GY) was performed by a two-way variance
analysis (two-way ANOVA) with the radiation time and
dose as dependent variables.
Results
Phenotypical changes of the radio-resistant rectal cancer
cell line (SNU-503R80Gy) compared to its parental cell
line (SNU-503)
Among the three pairs of radio-resistant rectal cancer
cell lines, the SNU-503 and SNU-503R80Gy cell lines
were selected for the functional study. Under normal
growth condition, radio-resistant rectal cancer cells
(SNU-503R80Gy) grew 1.6 times faster than its parental
cells (SNU-503). When exposed to 4 Gy, the growth rate
of radio-resistant rectal cancer cells was decreased by
11.0% whereas that of parental cell line was declined by
35.1% (Fig. 1a) (* P < 0.05). The higher survival rate of
radio-resistant rectal cancer cells under irradiation was
confirmed again by MTT assay (Fig. 1b) (* P < 0.05). A
soft agar colony formation assay was conducted. Under
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normal growth condition, SNU-503R80Gy formed 82
visible colonies in average while SNU-503 formed no
colonies. Under 4 Gy, SNU-503R80Gy formed 16 visible
colonies in average whereas SNU-503 formed no col-
onies (Fig. 1c). The cleavage of poly-(ADP-ribose) poly-
merase (PARP) and caspase-3 was also examined under
4 Gy irradiation. The basal level of cleaved PARP and
caspase-3 was declined in radio-resistant rectal cancer
cells compared to that of rectal cancer cells. Although
cleavage level of both PARP and caspase-3 was increased
after 4 Gy irradiation, there was no evident difference
between radio-resistant and its parental rectal cancer
cells (Fig. 1d). A cell cycle analysis was performed to
check if DNA damage induced cellular senescence.
Overall, the G2/M phase of both SNU-503 and
SNU-503R80Gy cell lines increased by 29.3 and 23.7%,
respectively. However, there was no significant difference
between the two cell lines (Fig. 1e and f).
Differential mRNA expression in the induced radio-resistant
rectal cancer cell lines
A microarray was performed on three pairs of parental
and induced radio-resistant rectal cancer cell lines
(SNU-61, SNU-61R80Gy, SNU-283, SNU-283R80Gy,
SNU-503, and SNU-503R80Gy) in order to identify dif-
ferential mRNA expressions. When classified with fold
Fig. 1 Cellular changes in the induced radio-resistant rectal cancer cell lines based on the cell proliferation assay, colony forming assay, apoptotic
assay and cell cycle analysis. Cell counting a and MTT assay b were performed in the SNU-503 and SNU-503R80Gy cell lines 96 h after irrdiation
with 0 and 4 Gy. c For the colony forming assay, the number of colonies were averaged from three wells. d Cellular apoptosis was observed by
western blot analysis with cleaved PARP and Caspase-3 protein levels. Cell cycle analysis was performed by FACS (e and f). The entire experiments
were repeated three times. (* P < 0.05: comparison of cell proliferation between when the cell line was irradiated with 0 and 4 Gy, ** P < 0.0001:
comparison of the number of colonies between the parental and the induced radio-resistant rectal cancer cell lines, # P < 0.0002: comparison of the
number of colonies between when the cell line was irradiated with 0 and 4 Gy of irradiation)
Kim et al. BMC Cancer  (2018) 18:594 Page 5 of 14
change (FC) > 2 as the threshold of differential expres-
sion in the induced radio-resistance rectal cancer cell
lines, 26 genes had more than one-fold increase, and
seven genes had more than one-fold decrease (Fig. 2).
Clustering was done to categorize genes and cell lines
according to their FC. All three parental cell lines
(SNU-61, SNU-283, and SNU-503) were clustered
together. Among the induced radio-resistant rectal
cancer cell lines, SNU-283R80Gy had analogous mRNA
expression pattern with the parental cell lines.
SNU-61R80Gy and SNU-503R80Gy were clustered
separately (Fig. 2a). Most of the differently expressed
genes were related to hypoxia, oxygen levels, oxidation
reduction, regulation of epithelial cell differentiation,
and cell-cell adhesion according to the gene ontology
analysis (Table 1).
Potential target genes for acquiring radio-resistance
were further sorted with FC > 3 threshold, and five genes
(NDRG1, ERRFI1, H19, MPZL3, and UCA1) were se-
lected (Table 2). Real-time PCR (Fig. 3b, c, d, e, and f )
confirmed that the mRNA expression patterns of the five
genes were analogous to the microarray analysis, and the
mRNA expression level of NDRG1 and ERRFI1 was
specifically increased in the induced radio-resistant
rectal cancer cells.
ERRFI1 as the radio-resistant candidate marker gene
The protein expression of ERRFI1 in three pairs of the
induced rectal cancer cell lines was confirmed by West-
ern Blot analysis (Fig. 5a). Although the increased pro-
tein level in SNU-283R80Gy compared to its parental
cell lines was observed, it was obscure to determine the
protein expression in the SNU-61 and SNU-503 pairs. In
order to further verify the protein expression and cellu-
lar localization of ERRFI1, immunofluorescent staining
was performed in SNU-503 and SNU-503R80Gy cell
lines (Fig. 4). ERRFI1 was mainly localized in cytoplas-
mic regions and clearly augmented in SNU-503R80Gy.
To confirm the function of overexpressed ERRFI1,
siERRFI1 was transfected into the SNU-503R80Gy cell
Fig. 2 Microarray analysis of the parental and induced radio-resistant rectal cancer cell lines. a Thirty-three genes with fold change (FC) > 2 as the
threshold of differential expression were identified and clustered according to their mRNA expression level. b After normalization, 26 genes had
more than one-fold increase, and seven genes had more than one-fold decrease
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line. The knock-down efficiency of siERRFI1 was
accessed by RT-PCR (Fig. 5b). When ERRFI1 was
down-regulated, there was no significant change to cell
proliferation based on cell counting and MTT assay after
0 and 4 Gy of irradiation (Fig. 5c and d).
NDRG1 as the radio-resistant candidate marker gene
The SNU-61 and SNU-61R80Gy cell lines were excluded
from the functional study due to their slow growth rates.
Instead, previously established radio-resistant rectal cell
lines (SNU-977, SNU-977R80Gy, SNU-1411, and
SNU-1411R80Gy) were included to screen the basal
protein level of NDRG1 in the radio-resistance cell
lines compared to their parental cell lines. Only
SNU-283R80Gy and SNU-503R80Gy showed increased
protein levels for NDRG1 compared to their parental cells.
Due to the intrinsic NDRG1 expression of the SNU-283
cell line, SNU-503 and SNU-503R80Gy were selected for
Table 1 Gene ontology analysis of altered genes in radio-resistant rectal cancer cell lines
Probe Set ID Gene symbol GO_BP SNU-61 FC SNU-283 FC SNU-503 FC
P R P R P R
7912157 ERRFI1 288 1288 4.5 52 206 4.0 334 1215 3.6
7938390 ADM ● ◎ 178 746 4.2 185 524 2.8 222 469 2.1
7945680 H19 79 1562 19.8 65 265 4.1 74 6924 93.8
7952036 MPZL3 100 509 5.1 86 297 3.5 75 324 4.3
7954090 EMP1 654 1493 2.3 66 1171 17.8 811 3459 4.3
7978544 EGLN3 ● ◎ ◑ 114 304 2.7 117 376 3.2 93 515 5.6
8004360 KCTD11 44 95 2.1 37 78 2.1 82 196 2.4
8020762 DSG3 ◯ 53 450 8.5 29 98 3.4 800 1741 2.2
8022711 DSC2 ◯ 589 1463 2.5 481 1017 2.1 561 1651 2.9
8026490 UCA1 485 1434 3.0 38 121 3.1 37 1153 31.3
8027002 GDF15 318 1203 3.8 332 843 2.5 73 255 3.5
8037374 PLAUR 109 228 2.1 59 152 2.6 49 115 2.4
8041508 QPCT 90 197 2.2 26 58 2.2 10 48 4.8
8051322 XDH ◑ ◐ 40 101 2.5 44 142 3.2 51 105 2.1
8077441 BHLHE40 240 904 3.8 193 470 2.4 178 476 2.7
8113214 GLRX ◑ 32 90 2.8 116 459 4.0 31 133 4.3
8119161 PIM1 128 608 4.7 238 637 2.7 265 851 3.2
8123598 SERPINB1 443 1015 2.3 856 1918 2.2 81 271 3.3
8141328 CYP3A5 ◑ 350 785 2.2 283 998 3.5 16 46 3.0
8145454 BNIP3L 158 811 5.1 269 551 2.0 403 944 2.3
8150881 PLAG1 29 136 4.6 18 37 2.0 76 165 2.2
8153002 NDRG1 208 3499 16.8 463 1615 3.5 436 2010 4.6
8012953 TRIM16 ◐ 159 337 2.1 86 263 3.0 384 866 2.3
8054377 FHL2 165 505 3.1 157 451 2.9 49 124 2.5
8119898 VEGFA ● ◎ 168 550 3.3 210 538 2.6 396 794 2.0
7969438 LMO7 ● 273 666 2.4 179 557 3.1 48 320 6.6
7927915 STOX1 29 14 −2.1 47 17 −2.8 108 18 −5.9
7979281 WDHD1 288 114 −2.5 109 54 −2.0 238 96 −2.5
7996211 GINS3 115 41 −2.8 88 38 −2.3 159 58 −2.8
8017210 AP1S2 43 15 −2.9 82 32 −2.6 134 45 −3.0
8060813 MCM8 259 122 −2.1 340 170 −2.0 526 165 −3.2
8083656 MFSD1 665 301 −2.2 1212 530 −2.3 865 354 −2.4
8155327 ALDH1B1 ◑ 214 81 −2.6 1622 566 −2.9 299 133 −2.3
Genes that differently expressed more than 2-folds in radio-resistant rectal cancer cell lines were analyzed with gene ontology. (P: Parental rectal cancer cell line, R:
Radio-resistant rectal cancer cell line, FC: Fold change, ●: Response to hypoxia, ◎: Response to oxygen levels, ◑: Oxidation reduction,◐: Regulation of epithelial cell
differentiation, and ◯: Cell-cell adhesion)
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the further functional study (Fig. 6a). The protein expres-
sion of NDRG1 was suppressed with short hairpin RNA
targeting NDRG1, and the knock-down efficacy was
accessed by Western Blot analysis (Fig. 6b). Cells were ex-
posed to 12Gy of radiation and harvested at various time
intervals (6, 24, 48, and 72 h). Immunocytochemistry re-
vealed that both active forms of caspase-3 and phosphory-
lated gamma H2AX were decreased in SNU-503R80Gy
cells compared to SNU-503 cells. When NDRG1 was
down-regulated in SNU-503R80Gy, cells were damaged
again from ionizing radiation and both active forms of
caspase-3 and phosphorylated gamma H2AX were de-
tected in a similar level with SNU-503, naïve cells (Figs. 7,
and 8). Western Blot analysis revalidated that
SNU-503R80Gy with down-regulated NDRG1 was more
sensitive to initial damage induction (6–24 h after irradi-
ation) than SNU-503R80Gy parental cells (Fig. 6c and 7).
After 72 h, SNU-503R80Gy parental cells repaired damage
more effectively than SNU-503R80Gy shNDRG1 cells
(Fig. 6c and 8). This was re-confirmed by time-dependent
cell proliferation assay. Until 72 h after irradiation, the
proliferation rate of SNU-503R80Gy cells with mock
vector and shNDRG1 was similar. In 96 h, the
Table 2 List of genes that were up-regulated more than 3-folds
in radio-resistant rectal cancer cell lines
Gene symbol Description FCa
ERRFI1 ERBB receptor feedback inhibitor 1 3.6
H19 Imprinted maternally expressed transcript 4.1
MPZL3 Myelin protein zero-like 3 3.5
NDRG1 N-myc downstream regulated 1 3.0
UCA1 Urothelial cancer associated 1 3.5
Five candidate genes were selected for functional study in accordance with
3-folds up-regulation in the induced radio-resistant rectal cancer cell lines
FC Fold change
athe lowest fold change out of three paired rectal cancer cell lines
Fig. 3 Potential target genes for acquiring radio-resistance were further sorted with FC > 3 threshold, and five genes (NDRG1, ERRFI1, H19, MPZL3,
and UCA1) were selected. RT-PCR (a) and real-time PCR (b, c, d, e, and f) confirmed that the mRNA expression patterns of the five genes were
analogous to the microarray analysis (P: parental rectal cancer cell line, R: radio-resistant rectal cancer cell line, N: negative control)
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Fig. 4 Subcellular localization and expression of the ERRFI1 and NDRG1 proteins in SNU-503 and SNU-503R80Gy
Fig. 5 Expression level of the ERRFI1 and its role in cell proliferation under irradiation in the SNU-503 and SNU-503R80GY cell lines. a The protein
expression of ERRFI1 in three pairs of the induced rectal cancer cell lines was confirmed by Western Blot analysis (P: Parental rectal cancer cell
line, R: Radio-resistant rectal cancer cell line) were performed. b The knock-down efficiency of siERRFI1 in SNU-503R80Gy cell line was accessed by
RT-PCR. Cell counting c and MTT assay d were performed 96 h after siERRFI1 transfection (N: Negative control)
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proliferation rate of SNU-503R80Gy shNDRG1 was
declined significantly (Fig. 6d).
Discussion
Preoperative radiotherapy combined with total mesorec-
tal excision for resectable rectal cancer has been
performed as a prevalent therapeutic and preventative
measure for treating colorectal cancer [2]. Preoperative
short-term radiotherapy reduced 10-year local recur-
rence by more than 50% from just surgery alone and
significantly improved the 10-year survival in patients
with a negative circumferential margin [3]. Nevertheless,
patients who experience tolerance to radio-therapy still
suffer from relapsed rectal cancer [4]. While numerous
genes have been screened for explaining resistance to
radiotherapy, the heterogenetic background of recurred
rectal cancer after preoperative irradiation accentuates
the need for more databases that represent various gen-
etic landscapes.
In this study, three human rectal cancer cell lines
(SNU-61, SNU-283 and SNU503) were exposed to re-
peated 4 Gy dose fractions and allowed to recover to a
set confluence of 70% in between fractions. Increased
growth rate and colony forming ability are known as
general consequence of fractionated radiation exposure
and are often involved in a modification of cell cycle
distribution [15]. The cumulative exposure of human
rectal cancer cells to 80 Gy fractionated radiation re-
sulted in the generation of a sub-line with a significantly
increased proliferation rate and clonogenic survival po-
tential following radiation exposure, when compared to
mock irradiated, aged-matched cells (Fig. 1a, b and c).
It is reported that radio-resistance is maintained by
G2/M cell cycle arrest [16]. Compared to the SNU-503,
G2/M phase was increased more in SNU-503R80Gy
when exposed to 4 Gy-dose radiation. This may suggest
that SNU-503R80Gy cells resisted the damage from ion-
izing irradiation by arresting its cell cycle at the G2/M
phase. Further evaluation of the underlying mechanisms
for the amplification of the G2/M-phase cell population
is warranted.
Cleaved PARP and active form of the caspase-3 has
become a useful hallmark of apoptosis [17]. Compared
to the SNU-503, the basal protein expression of both
cleaved PARP and the active form of the caspase-3 was
decreased in SNU-503R80Gy (Fig. 1d). Given that both
SNU-503 and SNU-503R80Gy grew as irregular convex
aggregates in which cells at the center of the aggregates
may experience hypoxic damage, a decreased cleaved
PARP and active form of the caspase-3 in the induced
radio-resistance rectal cancer cells may imply that the
mechanism of radio-resistance is associated with
Fig. 6 The effect of down-regulated NDRG1 in the radio-resistant rectal cancer cells. a Western blot analysis was performed to confirm the basal
protein expression of NDRG1. SNU-283R80Gy and SNU-503R80Gy cells had increased level of NDRG1 compared to their parental cells. b
Knockdown efficacy of NDRG1 with short-hairpin RNA was confirmed with Western blot analysis. c Down-regulated NDRG1 increased the
sensitivity of radio-resistance rectal cancer cells to irradiation. The amount of cleaved PARP and phosphorylated gamma H2AX was augmented
when the expression of NDRG1 was decreased. d Cell Proliferation rate was decreased when NDRG1 was down-regulated
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resistance to cellular hypoxia. This notion was
re-encapsulated by gene ontology analysis from the micro-
array. Most of the differently expressed genes in the
radio-resistant rectal cancer cells were related to hypoxia,
oxygen levels, oxidation reduction, regulation of epithelial
cell differentiation, and cell-cell adhesion according to the
gene ontology analysis (Table 1). The mechanistic com-
parison of resistance to radiation and hypoxia should be
further investigated.
ERRFI1 acts as a negative feedback regulator of the
EGF receptor and is also known as Mig6, RALT, or
GENE33 [18]. ERRFI1 directly interacts with four mem-
bers of the ERBB family and works as a negative feed-
back regulator of the ERBB RTK pathway [19] by acting
as a negative regulator of skin morphogenesis and tumor
formation [9]. There has also been evidence that ERRFI1
acts as a tumor-suppressor gene [20]. In various cancers
such as skin, breast, pancreatic, and ovarian, ERRFI1 has
been strongly down-regulated. However, there have been
no reports on this gene in colorectal cancer cell lines. In a
recent study, it was discovered that the down-regulation
of ERRFI1 enhances resistance to MEK inhibition in KRAS
mutant cancer cells [21]. In this present study, the basal
mRNA and protein level of ERRFI1 was up-regulated in
the induced radio-resistant human rectal cancer cell lines.
Nevertheless, radio-resistant rectal cells showed increased
proliferation rates after ERRFI1 was down-regulated by
siRNA (Fig. 5c, d). As mentioned previously, ERRFI1 is
known to work as a negative feedback regulator of the
ERBB RTK pathway, so attenuated ERRFI1 might increase
the ERBB RTK pathway and lead to increased cell growth.
The N-myc downstream-regulated gene 1(NDRG1)
has been reported as a potential metastasis suppressor
by maintaining the localization of E-cadherin and
β-catenin in prostate and colon cancer cells [13]. In
addition, the neuroblastoma study revealed that NDRG1
is associated with increased level of resistant-related
proteins such as MDR, LRP-1, and MRP-1 [14]. Accord-
ing to HPA dataset from The Human Protein Atlas, the
protein expression of NDRG1 in normal rectum tissue
Fig. 7 Six hours after 12 Gy irradiation, immunocytochemistry revealed that both active forms of caspase-3 and phosphorylated gamma H2AX
were expressed in SNU-503, SNU-503R80Gy and SNU-503R80Gy shNDRG1
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was relatively low (24th out of 37 organs tested). On the
other hands, the protein expression of NDRG1 in colo-
rectal cancer was medium to high (8th out of 20 organs
tested). Although few studies have shown that NDRG1
expression may be associated with less aggressive
colorectal cancer [22, 23], association between NDRG1
and prognostic features in rectal cancer remained
unknown [24]. Moreover, the relationship between the
protein expression of NDRG1 and resistance to ionizing
radiation in rectal cancer cell lines has not been studied.
In the present study, both mRNA (Fig. 3a) and protein
expression (Fig. 6a) of NDRG1 were significantly
augmented when SNU-283 and SNU-503 cells acquired
resistance to ionizing radiation. Phosphorylation of
gamma H2AX has been a biomarker for DNA
double-strand breaks [25]. Immunocytochemistry re-
vealed that both active forms of caspase-3 and phos-
phorylated gamma H2AX were decreased in
SNU-503R80Gy cells compared to SNU-503 cells. When
NDRG1 was down-regulated in SNU-503R80Gy, cells
were damaged again from ionizing radiation and both
active forms of caspase-3 and phosphorylated gamma
H2AX were detected in a similar level with SNU-503,
naïve cells (Figs. 7 and 8). Western Blot analysis revali-
dated that SNU-503R80Gy with down-regulated NDRG1
was more sensitive to initial damage induction (6–24 h
after irradiation) than SNU-503R80Gy parental cells
(Figs. 6c and 7). After 72 h, SNU-503R80Gy parental
cells repaired damage more effectively than
SNU-503R80Gy shNDRG1 cells (Figs. 6c and 8). This
may imply that down-regulation of NDRG1 re-sensitized
SNU-503R80Gy cells by disrupting rapid DNA damage
recovery mechanism of radio-resistant rectal cancer
cells. This was re-confirmed by time-dependent cell pro-
liferation assay. Until 72 h after irradiation, the prolifera-
tion rate of SNU-503R80Gy cells with mock vector and
Fig. 8 Seventy-two hours after 12 Gy irradiation, immunocytochemistry revealed both active forms of caspase-3 and phosphorylated gamma
H2AX were decreased in SNU-503R80Gy cells whereas SNU-503 and SNU-503R80Gy NDRG1 cells strongly expressed both active forms of caspase-3
and phosphorylated gamma H2AX
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shNDRG1 was similar. In 96 h, the proliferation rate of
SNU-503R80Gy shNDRG1 was declined significantly
(Fig. 6d).
Radio-resistance has been known to be associated with
DNA damage repair mechanism. Glioma study revealed
that DNA damage repair activity of Ape1/Ref-1 deter-
mined radiation resistance in glioma cells as there was a
dose-dependent relationship between increasing Ape1
overexpression and increasing radio-resistance [26]. The
role of NDRG1 in response to DNA damage has not
reached an agreement. Siavash K. Kurdistani reported
that DNA-damaging agents induced NDRG1 expression
in a p53-dependent manner but independent of a
p53-mediated G1 arrest. Beside, NDRG1 was
re-localized from cytoplasmic region to the nucleus
upon DNA damage [27]. On the other hands, other
studies have shown no correlation between Ndrg-1 ex-
pression and DNA damage, despite the upregulation of
p53 [28, 29].
Our study indicated that NDRG1-overexpressing
SNU-503R80Gy cells began to recover from DNA
damage after 72 h of irradiation. When the NDRG1 ex-
pression was down-regulated, the radio-resistant cells
failed to recover from the DNA damage and the cell
proliferation rate was decreased. We suggest that the
augmented protein expression of NDRG1 is involved in
DNA damage repair mechanism. Which DNA repair
regulators are associated with NDRG1 should be further
investigated.
Conclusion
Taken together, we suggest that the higher NDRG1 ex-
pression may be associated with the radio-resistance of
human rectal cancer cells, and it can be a potential
therapeutic target for re-sensitizing radio-resistant rectal
cancer cells to ionizing radiation.
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